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OBJECTIVE—Vascular endothelial growth factor (VEGF),
which is associated with the stimulation of angiogenesis and
collateral vessel synthase, is one of the crucial factors involved in
cardiac remodeling in type 2 diabetes.
RESEARCH DESIGN AND METHODS—We investigated
VEGF inhibition by dRK6 on the heart in an animal model of type
2 diabetes. Male db/db and db/m mice either were treated with
dRK6 starting at 7 weeks of age for 12 weeks (db/db-dRK6 and
db/m-dRK6) or were untreated.
RESULTS—Cardiac dysfunction and hypertrophy were noted by
echocardiogram and molecular markers in the db/db-dRK6 mice.
The presence of diabetes signiﬁcantly suppressed the expression
of VEGF receptor (VEGFR)-1 and VEGFR-2, phospho-Akt, and
phospho-endothelial nitric oxide synthase (eNOS) in the heart. In
db/db-dRK6 mice, dRK6 completely inhibited VEGFR-2, phospho-
Akt, and phospho-eNOS expression, whereas no effect on
VEGFR-1 was observed. Cardiac ﬁbrosis, microvascular scarcity
associated with an increase in apoptotic endothelial cells, and
inﬂammation were prominent, as well as increase in antiangio-
genic growth factors. Cardiac 8-hydroxy-deoxyguanine and
hypoxia-inducible factor-1 expression were signiﬁcantly in-
creased. No such changes were found in the other groups,
including the db/m-dRK6 mice. The number of apoptotic human
umbilical vein endothelial cells was increased by dRK6 in a
dose-dependent manner only at high glucose concentrations,
and this was associated with a decrease in phospho-Akt and
phospho-eNOS related to oxidative stress.
CONCLUSIONS—Our results demonstrated that systemic
blockade of VEGF by dRK6 had deleterious effects on the heart
in an animal model of type 2 diabetes; dRK6 induced downregu-
lation of the VEGFR-2 and Akt-eNOS axis and enhancement of
oxidative stress. Diabetes 58:2666–2676, 2009
V
ascular endothelial growth factor (VEGF), espe-
cially VEGF-A, is an important mediator of neo-
vascularization, as well as a key factor for
maintaining the integrity of endothelial cells in
physiologic and pathologic conditions. Two important
VEGF receptor tyrosine kinases have been identiﬁed and
their functions described (VEGF receptor [VEGFR]-1 or
Flt-1 and VEGFR-2 or KDR/Flk-1) (1). The deregulation of
VEGF results in reduced activation of endothelial nitric
oxide synthase (eNOS) and increased production of reac-
tive oxygen species (ROS), which upregulates the expres-
sion of procoagulant, prothrombotic, and proinﬂammatory
mediators (2). Several VEGF inhibitors are currently under
evaluation or have already been approved for the treat-
ment of age-related macular degeneration and macular
edema (3), various cancers (4,5), and diabetic microvas-
cular complications (3). However, there is a growing
realization that VEGF inhibitors have signiﬁcant side ef-
fects on the kidney and blood pressure and have been
associated with thrombotic microangiopathy, which are
typically downstream consequences of suppression of the
endothelial Akt-eNOS signaling pathway (4). Impaired
cardiac function has been observed in some patients on
anti-VEGF therapy (4).
Diabetic cardiomyopathy (DCM) is a clinical condition
associated with ventricular dysfunction; DCM develops in
patients with diabetes in the absence of atherosclerosis
and hypertension (6–9). Left ventricular diastolic and
systolic dysfunction and alterations in the coronary micro-
circulation, as well as interstitial ﬁbrosis, are characteris-
tics of DCM because of a reduced microvasculature (10–
12). There continues to be debate about the role of VEGF
with regard to the heart in diabetic patients. Expression of
VEGF and VEGFR-2 in the human heart, and in streptozo-
tocin-induced diabetic animals, has been shown to be
signiﬁcantly decreased because of loss of insulin-induced
VEGFR-eNOS axis activation (13–15), which is followed
by an increase of apoptosis in endothelial cells, a decrease
in the number of circulating endothelial progenitor cells,
decreased capillary density, and impaired myocardial per-
fusion (14–16). Downregulation of VEGF in the heart is
associated with an increased risk for cardiovascular mor-
bidity and mortality in diabetic patients (16). Both in-
creased and unaltered serum or plasma VEGF levels were
observed in type 1 and 2 diabetic patients versus control
subjects (17,18). On the other hand, the serum VEGF level
is increased in patients with diabetic symptomatic poly-
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artery disease, particularly related to the extent of myo-
cardial damage (19–21).
dRK6 is an arginine-rich anti-VEGF hexapeptide and a
d-amino acid derivative of RK6 (Arg-Arg-Lys-Arg-Arg-Arg).
dRK6 binds with VEGF-A and can thereby block the interac-
tion between VEGF-A (mainly VEGF165 and VEGF121) and
the VEGFRs. In a previous study, dRK6 showed signiﬁcant
inhibition of VEGF-induced angiogenesis and retarded the
growth and metastasis of colon carcinoma cells without
direct cytotoxicity (22). dRK6 is stable, and its half-life at
37°C in the serum is 13.5 h (22). Previous results demon-
strated that a subcutaneous injection of dRK6 (25–50 g)
every other day for 3 weeks reduced the incidence and
severity of collagen-induced arthritis in a dose-dependent
manner without any toxicity (22,23).
Therefore, we determined whether systemic VEGF
blockade, using dRK6, could lead to structural and func-
tional deterioration of the heart in db/db mice in a murine
model of type 2 diabetes.
RESEARCH DESIGN AND METHODS
Experimental methods. All experiments were performed according to the
institutional animal care guidelines, and the investigation conformed with the
Guide for the Care and Use of Laboratory Animals published by the U.S.
Institutes of Health (National Institutes of Health Publication No. 85–23,
revised 1996). Six-week-old male C57BLKS/J db/db and db/m mice were
purchased from Jackson Laboratories (Bar Harbor, ME); db/m mice were used
as controls in all of the experiments. Fifty micrograms of dRK6 was admin-
istered three times per week by intraperitoneal injection to db/m (db/m-dRK6)
or db/db (db/db-dRK6) mice (n  8) beginning at 7 weeks of age for 12 weeks
(n  8). The diabetic db/db (db/db) and nondiabetic db/m control groups
(db/m) received only PBS.
After 12 weeks of treatment, the systolic blood pressure was determined by
the noninvasive tail cuff system in conscious mice (IITC Life Science,
Woodland Hill, CA) after a 5-day accommodation. At the end of the study, the
animals were anesthetized and killed.
Measurement of serum parameters. Blood was collected from the left
ventricle and centrifuged; the plasma was stored at 70°C for subsequent
analyses. The A1C was measured by high-pressure liquid chromatography
(BioRad, Richmond, CA). The total cholesterol, triglycerides, free fatty acids
(FFAs), and insulin concentrations were measured by an autoanalyzer (Wako,
Osaka, Japan). We also measured the serum VEGF concentration using an
ELISA kit (Komabiotech, Seoul, South Korea).
Assessment of heart function. During the last week of the study, we
performed an echocardiogram to evaluate the heart function and size in the
animals using a Hewlett-Packard Sonus 4500 ultrasound machine (Agilent
Technologies, Edmonton, AB, Canada) while the animals were anesthetized
according to a procedure previously reported (24).
Light microscopy. The heart samples were collected after systemic perfusion
with PBS and then ﬁxed in 4% paraformaldehyde. To examine the effect of
dRK6 on cardiac ﬁbrosis, the analysis was performed on trichrome-stained
heart sections as described previously (25). Ten consecutive heart cross-
sections were photographed by an examiner who was blinded to the source
of the tissue using a digital camera (Olympus DP11; Olympus America,
Melville, NY).
Immunohistochemistry for connective tissue growth factor, platelet-
endothelial cell adhesion molecule-1, thrombospondin-1, trans-
ferase-mediated dUTP nick-end labeling, F4/80, and 8-hyrdoxy-
deoxyguanosine (8-OH-dG). We performed immunohistochemistry for
connective tissue growth factor (CTGF), F4/80, platelet-endothelial cell adhe-
sion molecule (PECAM)-1, thrombospondin-1, transferase-mediated dUTP
nick-end labeling (TUNEL), and 8-hyrdoxy-deoxyguanosine (8-OH-dG). Five-
m thick sections were incubated overnight with anti-CTGF as a proﬁbrotic
growth factor (1:250 in blocking solution; Abcam, Cambridge, U.K.), anti–
PECAM-1 as a mouse endothelial cell marker (1:50; BD Bioscience, San Diego,
CA), antithrombospondin-1 as an antiendothelial cell growth factor (1:100;
Lab Vision, Fremont, CA), the in situ TUNEL assay as an apoptotic marker
(Apoptag Plus, Intergen, New York, NY), anti-F4/80 as an inﬂammatory cell
marker (1:50; Serotek, Oxford, U.K.), and 8-OH-dG as a marker of oxidative
DNA damage (1:100; JalCA, Shizuoka, Japan) in a humidiﬁed chamber at 4°C.
Antibodies were localized with the ABC technique (Vector, Buringame, CA).
We also measured 8-OH-dG levels from the puriﬁed DNA of the hearts
performed with an ELISA kit.
For the quantiﬁcation of the proportions of the areas stained, 20 views
were randomly located in the middle portion of the myocardium of each slide
(Scion Image Beta 4.0.2; Frederick, MD). The endothelial cells that were
positive for apoptosis exhibited an intense brown nuclear (TUNEL-positive)
and a red cytoplasmic colorimetric (PECAM-1–positive) reaction product. The
number of cells positive for the TUNEL reaction was determined in the
myocardium under 400 magniﬁcation.
Immunoﬂuorescent staining for the hypoxia-inducible factor-1. To
evaluate the hypoxic injury to the heart, we performed hypoxia-inducible
factor (HIF)-1 immunoﬂuorescent staining of the heart (1:50; Novous Bio-
logical, Littleton, CO). For quantiﬁcation of the proportion of the area stained,
20 views (200 magniﬁcation), randomly located in the middle portion of
the myocardium of each slide, were also examined (Scion Image Beta 4.0.2).
Western blot and semi-quantitative RT-PCR for total- and phospho-
eNOS (Ser
1177), total- and phospho-Akt (Ser
473), VEGFR-1, VEGFR-2,
CTGF, and HIF-1. Western blot analysis was performed using the following
antibodies: total Akt, phospho-Akt (Ser
473), total eNOS, and phospho-eNOS
(Ser
1177; all from Cell Signaling Technology, Danvers, MA) and HIF-1, CTGF,
and -actin (all from Abcam, Cambridge, U.K.). Protein for HIF-1 from
nuclear fractions of the hearts was isolated using a nuclear extraction kit
(Cayman Chemical, Ann Arbor, MI) following the manufacturer’s protocol. We
also performed RT-PCR to assess the levels of gene expression of VEGFR-1
and -2, HIF-1, CTGF, and 18r rRNA as an internal control. Primers for
ampliﬁcation of VEGFR-1 and -2, HIF-1, CTGF, and 18r rRNA are listed in
the supplemental data available in an online appendix at http://
diabetes.diabetesjournals.org/cgi/content/full/db09-0136/DC1.
Quantitative PCR for atrial natriuretic factor, B-type natriuretic pep-
tide, -myosin heavy chain, and -myosin heavy chain. Total reactive
nitrogen species was performed using an ABI PRISM Sequence Detector
System 7500 (Applied Biosystems, Foster City, CA). The PCR primers for atrial
natriuretic factor (ANF), B-type natriuretic peptide (BNP), -myosin heavy
chain (MHC), and -MHC are listed in the supplemental data.
TUNEL assay, 8-iso-PGF2 and 8-OH-dG levels in the human umbilical
vein endothelial cell culture. Human umbilical vein endothelial cells
(HUVECs) were cultured in RPMI 1640 supplemented with 10% FBS and 15
mg/500 ml of endothelial cell growth supplement (Sigma, St. Louis, MO) at
37°C in a humidiﬁed, 5% CO2/95% air atmosphere. Apoptosis was quantiﬁed
with the in situ cell death detection kit, using a TUNEL assay (Chemicon
International, Temecula, CA). After treatment with different concentrations of
D-glucose in the media (5 and 30 mmol/l per liter of D-glucose and D-glucose [5
mmol/l per liter]  D-mannitol [25 mmol/l per liter]) with 0, 10
6,1 0
8,o r1 0
10
mmol/l dRK6 for 48 h, the number of TUNEL-positive cells was counted in 10
randomly chosen ﬁelds at a magniﬁcation of 400. We also performed
Western blot analysis using 10
8 mmol/l dRK6 for 48 h with the following
antibodies: total Akt, phospho-Akt (Ser
473), total eNOS, and phospho-eNOS
(Ser
1177). To evaluate the direct effects of dRK6 on oxidative stress, we also
measured the concentrations of 8-iso-PGF2 and 8-OH-dG in the cell culture
media.
Statistical analysis. Data are expressed as the means 	 SD. The differences
between the groups were examined for statistical signiﬁcance using ANOVA
with the Bonferroni’s correction (SPSS 11.5; Chicago, IL). Nonnormally
distributed data were analyzed by the nonparametric unpaired Mann-Whitney
U test. A P value 0.05 was considered a statistically signiﬁcant difference.
RESULTS
Body weight, heart weight, mean systolic blood pres-
sure, and the hematocrit. The body weights of the db/db
mice with or without dRK6 treatment were heavier than
the db/m mice at the end of the experiment (P 
 0.01,
Table 1). There was a slightly heavier heart weight in the
db/db-dRK6 group compared with the other groups, but
the difference was not statistically signiﬁcant. There was
no signiﬁcant difference in mean systolic blood pressure
(SBP) between the db/m and db/db mice with or without
dRK6 treatment.
Fasting blood glucose, A1C, serum lipids, insulin
levels, and serum VEGF. As expected, there were signif-
icant increases in the fasting blood glucose (FBG) and
A1C, total cholesterol, triglycerides, FFAs, and insulin
concentrations in the db/db and db/db-dRK6 mice com-
pared with the db/m and db/m-dRK6 mice (P 
 0.05, P 

0.01, or P 
 0.001, respectively; Table 1). By contrast, there
was no such difference observed between the db/db mice
and db/db-dRK6 mice. There were signiﬁcant increases in
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db/db-dRK6 mice compared with the db/m and db/db
control mice (P 
 0.001 and P 
 0.05, respectively). These
ﬁndings suggest that VEGF blockade with dRK6 signiﬁ-
cantly increased the circulating VEGF concentrations.
Assessment of heart function. To assess heart function,
we performed echocardiograms on the mice in the study
groups (Fig. 1A). There were no signiﬁcant differences in
the diastolic interventricular wall thickness (IVSTd), left
ventricular posterior wall thickness (LVPWTd), and left ven-
tricular mass (LVM) among the db/m, db/m-dRK6, and db/db
mice. By contrast, these parameters in the db/db-dRK6 mice
were markedly increased compared with the other groups
(P 
 0.05, Fig. 1B). Molecular markers of cardiac hypertro-
phy (ANF, BNP, -MHC, and -MHC) were also elevated in
the db/db-dRK6 mice (P 
 0.05, Fig. 1D). These results
suggest that dRK6 treatment caused development of cardiac
hypertrophy. Diabetic db/db mice also exhibited a persistent
decrease in fractional shortening (P 
 0.05, Fig. 1C) com-
pared with the db/m mice. There was a more prominent
decrease in the fractional shortening, mean velocity of cir-
cumferential ﬁber shortening (Vcf), and peak E/A ratio in the
db/db-dRK6 mice. These ﬁndings demonstrate that treatment
with dRK6 had a negative effect on the cardiac function in the
presence of diabetes.
Effect of dRK6 on VEGFR-1 and -2, Akt, and eNOS on
the heart. As shown in Fig. 2A–C, there were marked
decreases in the expression of VEGFR-1 and -2 mRNA in the
db/db control mice compared with the db/m mice. In addi-
tion, dRK6 treatment completely abolished the expression of
VEGFR-2 mRNA and protein in db/db-dRK6 mice. By con-
trast, there was no change in the expression of VEGFR-1
mRNA in db/db-dRK6 mice; no such changes were detected
in db/m-dRK6 mice. There was signiﬁcantly decreased ex-
pression of phospho-Akt protein, eNOS mRNA, and phospho-
eNOS protein in db/db mice compared with db/m mice (Fig.
2D–G). Consistent with the VEGFR-2 ﬁndings, dRK6 treat-
ment completely inhibited expression of phospho-Akt/eNOS
protein in db/db-dRK6 mice.
Histologic examination of the heart and effects on
connective tissue growth factor. In the db/m and db/db
control mice, there was no apparent cardiac ﬁbrosis
observed, which was likely because of the short period of
diabetes exposure (Fig. 3A and B). However, dRK6 treat-
ment markedly increased the cardiac ﬁbrosis observed in
the db/db-dRK6 mice (P 
 0.05, Fig. 3D and E). By
contrast, there was no such change observed in the
db/m-dRK6 mice (Fig. 3B). We also performed immuno-
staining, Western blot, and RT-PCR for CTGF to evaluate
the expression of proﬁbrotic and inﬂammatory growth
factors in the heart. Compared with the increased myocar-
dial ﬁbrosis in the heart, the positive staining for CTGF
was signiﬁcantly increased in the db/db-dRK6 mice com-
pared with the db/db and db/m-dRK6 mice (P 
 0.05, Fig.
4A–E). Consistent with the immunostaining results, the
expression of CTGF mRNA and protein levels was also
signiﬁcantly increased in the db/db-dRK6 mice (Fig. 4F and
G). These ﬁndings suggest that CTGF is one of the major
proﬁbrotic growth factors in dRK6-induced cardiac ﬁbrosis.
Immunohistochemistry for PECAM-1, TUNEL, throm-
bospondin-1, and F4/80. To evaluate vascular homeosta-
sis, we performed immunohistochemistry staining for
PECAM-1, PECAM-1TUNEL, and thrombospondin-1.
There were no changes in the expression of PECAM-1 in
db/db mice. By contrast, dRK6 treatment in db/db-dRK6
mice was associated with a decrease in expression of
PECAM-1 in the myocardium, reﬂecting a decrease in
endothelial cells (Fig. 5A–E). It is well known that throm-
bospondin-1 is an antiangiogenic peptide; therefore, we
evaluated the expression of thrombospondin–1 in the
heart. The expression of thrombospondin-1 was signiﬁ-
cantly increased in the db/db-dRK6 mice compared with
the db/m, db/m-dRK6, and db/db mice (P 
 0.05, Fig.
5F–J). Further evaluation of the effects of endothelial cell
apoptosis on the rare vessels in the heart was assessed by
double immunostaining with PECAM-1TUNEL in the
heart. It was difﬁcult to ﬁnd TUNEL-positive stained
endothelial cells in the db/m, db/m-dRK6, and db/db mice.
By contrast, an increased number of TUNEL-positive cells
were found in the db/db-dRK6 mice (P 
 0.001, Fig. 5K–O).
Only mild macrophage inﬁltration, as assessed by F4/80-
positive staining, was observed in the myocardium of
db/mb-dRK6 and db/db mice. By contrast, F4/80 immuno-
staining was markedly increased in the myocardium of
db/db-dRK6 mice (P 
 0.001, Fig. 4P–T).
Effect of dRK6 on HIF-1 and 8-OH-dG. There was no
difference in expression of HIF-1 in the hearts of db/m,
db/m-dRK6, and db/db mice. However, in db/db-dRK6
mice, expression of HIF-1 was signiﬁcantly increased
compared with the other groups (P 
 0.001, Fig. 6A–E).
The expression of HIF-1 protein and mRNA levels in the
heart signiﬁcantly increased in db/db-dRK6 mice (Fig.
6F–H). Diabetic db/db mice and db/m-dRK6 mice had
increased immunostaining of 8-OH-dG in the myocardial
cells compared with db/m mice (Fig. 6I). In the myocar-
dium, increased expression of 8-OH-dG (dark brown nu-
cleus) in db/db mice was markedly accentuated by
treatment with dRK6 (Fig. 6L and M). The 8-OH-dG levels
TABLE 1
Inﬂuence of dRK6 on physiologic and biochemical parameters and serum lipid proﬁles in db/db and db/m mice
db/m db/m-RK6 db/db db/db-RK6
Body weight (g) 31.6 	 1.2 31.2 	 1.3 50.3 	 5.8* 42.4 	 5.9*
Heart weight (g) 0.12 	 0.04 0.11 	 0.05 0.12 	 0.04 0.14 	 0.05
Mean SBP (mmHg) 95.6 	 5.4 97.6 	 3.5 99.1 	 6.2 102.3 	 5.0
Hematocrit (%) 34.0 	 2.9 35.6 	 3.4 39.8 	 5.2 38.6 	 6.4
Glucose (mmol/l) 11.2 	 1.1 11.8 	 1.9 58.0 	 5.9† 57.6 	 7.8†
A1C (%) 4.3 	 0.2 4.1 	 0.3 12.7 	 1.2† 13.6 	 1.0†
Total cholesterol (mmol/l) 1.66 	 0.38 1.53 	 0.34 2.08 	 0.37 1.92 	 0.31
Triglycerides (mg/dl) 60 	 16 66 	 20 103 	 27‡ 114 	 21‡
FFAs (mEq/l) 1.45 	 0.34 1.57 	 0.55 3.18 	 1.03‡ 3.76 	 1.19‡
Insulin (pg/ml) 0.17 	 0.13 0.19 	 0.14 0.50 	 0.14‡ 0.33 	 0.21‡
Serum VEGF (pg/ml) 1.25 	 1.73 23.5 	 7.7§ 6.6 	 3.9‡ 29.6 	 8.5§
Data are means 	 SD. *P 
 0.01, †P 
 0.001, ‡P 
 0.05 vs. dm and dm-dRK6. §P 
 0.001 vs. dm and P 
 0.05 vs. db/db.
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compared with db/db mice (Fig. 6M), the levels of which
were also increased compared with db/m mice. These
ﬁndings suggest that dRK6 treatment increased oxidative
stress in the hearts, especially in mice with diabetes.
Effect of dRK6 on HUVEC apoptosis. To examine the
direct role of dRK6 on HUVECs, we investigated whether
dRK6 induced apoptosis of the HUVECs using TUNEL
assay with different doses of dRK6 (10
6,1 0
8, and 10
10
mmol/l) and various concentrations of glucose in the
A 
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db/db db/db-dRK6
B 
C
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FIG. 1. Representative M-mode echocardiograms in diabetic db/db and nondiabetic db/m mice
with or without dRK6 treatment (A). Echocardiographic changes in IVSTd and LVPWTd, LVM
(B), fractional shortening, mean Vcf, and peak E/A ratio (C). Quantitative RT-PCR analysis for
ANF, BNP, -MHC, and -MHC transcript levels in hearts (D) from diabetic db/db and
nondiabetic db/m mice without (db/db, db/m) or with dRK6 treatment (db/db-dRK6, db/m-
dRK6) for 12 weeks beginning at 7 weeks of age. *P < 0.05, **P < 0.01 compared with other
groups.
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D-glucose  25 mmol/l mannitol) for 48 h. Only at a
concentration of 30 mmol/l of D-glucose were the HUVEC
TUNEL-positive cells signiﬁcantly increased in a dose-
dependent manner (P 
 0.01, Fig. 7). Treatment with dRK6
completely inhibited the expression of phospho-Akt and
phospho-eNOS protein with high glucose concentrations
in the media (Fig. 7B). However, there was no signiﬁcant
difference in phospho-Akt and phospho-eNOS protein ex-
pression for concentrations of 5 mmol/l D-glucose or 5
mmol/l D-glucose  25 mmol/l mannitol treated with or
without dRK6. As shown in Fig. 6F and G, the 8-iso-PGF2
and 8-OH-dG concentrations were increased with high
glucose concentrations, which were further increased by
dRK6 treatment (3.0- and 3.5-fold, respectively). However,
these changes were not observed at concentrations of 5
mmol/l D-glucose (low glucose) or 5 mmol/l D-glucose  25
mmol/l mannitol.
DISCUSSION
A growing number of drugs that inhibit VEGF signaling are
being considered for the treatment of cancer and diabetic
microvascular complications. These agents are generally
well tolerated but sometimes may be accompanied by
serious side effects. Most of the side effects are associated
with downstream effects of suppression of VEGF-NO
signaling through the inhibition of VEGF-A and VEGFR-2
signals in the endothelial cells of normal organs (4).
Therefore, we evaluated the role of VEGF inhibition using
dRK6 in the development and progression of cardiac
adverse effects in a model of type 2 diabetes (db/db mice).
In db/db mice, systemic dRK6 administration completely
inhibited the cardiac VEGFR-2–Akt-eNOS axis, which sub-
sequently caused the development of systolic dysfunction,
cardiac ﬁbrosis, and hypertrophy. From one perspective,
the deterioration caused by dRK6 might be related to the
regression of blood vessels, which was associated with an
increase in antiangiogenic growth factors, such as throm-
bospondin-1, transforming growth factor (TGF)-, and
CTGF. These events were accompanied by an increase in
endothelial cell apoptosis, inﬂammatory cell inﬁltration,
and myocardial ﬁbrosis. In addition, these pathologic
alterations led to the aggravation of hypoxic and oxidative
stress in the myocardium accompanied by metabolic ab-
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FIG. 2. RT-PCR for VEGF-R1, VEGF-R2 (A), eNOS (D) mRNA, and 18s rRNA expression in the hearts of diabetic db/db and nondiabetic db/m mice
with or without dRK6 treatment. Quantitative assessment of the expression of VEGF-R1 (B), VEGF-R2 mRNA (C), and eNOS mRNA (F)t o1 8 s
rRNA ratios in the hearts of the study groups. Western blot analysis of the total and phospho-Akt and phospho-eNOS (D) and quantitative
assessment of the expression of total and phospho-Akt (E) and phospho-eNOS protein (G). *P < 0.05 compared with other groups, **P < 0.01
compared with other groups, #P < 0.05 compared with the db/db group, P < 0.05 compared with the db/m group; n  4.
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the diabetic control or db/m-dRK6 mice. By using in vitro
HUVECs, we have shown that dRK6 had potent apoptotic
effects on endothelial cells, which were associated with
inhibition of the phospho–Akt-eNOS axis and enhance-
ment of oxidative stress.
To date, the effects of systemic inhibition of VEGF on
the heart remain uncertain. Previous ﬁndings from studies
of the structural and functional changes in the organs of
the normal adult mouse, after inhibition of VEGF signal-
ing, revealed little or no capillary regression was detected
in the brain, retina, skeletal muscle, lung, or myocardium
(26,27). Consistent with these ﬁndings, our study also
demonstrated that there was no change in the microvas-
culature in the heart of nondiabetic db/m mice. However,
there was signiﬁcant regression of the microvasculature of
the heart in the diabetic mice, which resulted in cardiac
ﬁbrosis and cardiac dysfunction. These ﬁndings suggest
that diabetes may be a critical determinant of the adverse
effects on the heart caused by systemic anti-VEGF therapy.
It has been shown that downregulation of expression of
myocardial VEGF and VEGFR-1 and -2 preceded all
other characteristic features of DCM (10). These ﬁnd-
ings suggest that downregulation of VEGF and VEGFR-2
is involved in the microvascular homeostasis of the
myocardium and thereby play a central role in the patho-
genesis of DCM. In addition, continuous and prolonged
VEGF blockade caused by deterioration of the DCM in
mice with type 2 diabetes appears to relate to the down-
regulation of the VEGFR-2–Akt-eNOS axis. The relation-
ship between VEGF expression, the microvasculature, and
cardiac function has been clearly demonstrated in exper-
iments on transgenic mice lacking VEGF isoforms,
VEGF164 and VEGF188. These mice exhibit impaired
myocardial angiogenesis and subsequently developed se-
vere left ventricular dysfunction (28,29). There is growing
evidence from animal models and patient studies that
DCM can result from microcirculatory defects in the absence
of epicardial coronary artery stenosis (30). These ﬁndings
suggest that decreased VEGF expression might play a signif-
icant role in the development of microvascular defects,
ischemia, and ﬁbrosis in the pathogenesis of DCM (13).
An important question with regard to VEGF blockade is
whether its effects on the heart are through metabolic
abnormalities and/or whether there is a direct effect of
VEGF on the cardiac microvasculature. Continuous dam-
age to endothelial cells by metabolic abnormalities, includ-
ing hyperglycemia, advanced glycosylation end products,
and FFAs, ultimately leads to cell loss, reduced blood ﬂow,
hypoxia, and tissue ischemia (31,32). The results of our in
vitro study suggest that metabolic abnormalities, espe-
cially hyperglycemia, have deleterious effects on the heart
related to VEGF blockade.
It is well known that hypoxia plays a key role in all
diabetes-related complications (33). Hyperglycemia-
induced oxidative stress is a major risk factor for the
development of microvascular pathology in the diabetic
myocardium and results in myocardial cell death, hyper-
trophy, ﬁbrosis, endothelial dysfunction, and even death
via the phosphatidylinositol 3-kinase and Akt signaling
pathways (34,35). Numerous studies have shown that Akt
promotes cardioprotection and inhibits cell apoptosis by
regulation of multiple substrates (36,37). Akt phosphorylates
and inactivates proapoptotic proteins including glycogen
synthase kinase-3 and caspase-9, the upstream activator of
caspase-3 (38,39). Akt also activates the antiapoptotic Bcl-2
protein, which is associated with phosphorylation of NOS
and increases in the production of NO. Therefore, downregu-
lation of the Akt-eNOS axis by dRK6 might relate to endo-
thelial cell apoptosis in diabetic db/db mice.
Under hypoxic conditions, HIF-1 is stabilized, translo-
cates into the nucleus, dimerizes with HIF-1, and up-
regulates the genes involved in angiogenesis, glycolytic
energy metabolism, cell proliferation, and survival (40,41).
In the present study, the markedly upregulated expression
of nuclear HIF-1 after treatment with dRK6 suggests that
the dRK6-induced hypoxic conditions in the heart and
HIF-1 function to prevent excessive ROS production
under conditions of chronic hypoxia. These results indi-
cate that continuous VEGF blockade by dRK6 under
diabetic conditions ultimately leads to the accumulation of
reactive oxygen species and oxidative stress leading to
increased expression of 8-OH-dG in the heart.
Previous reports have demonstrated that db/db mice
usually have no gross cardiac hypertrophy at 3 months
(42,43); isolated working hearts as well as studies using
magnetic resonance imaging, however, indicate that sig-
niﬁcant left ventricular dysfunction develops in the hearts
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FIG. 3. Cardiac histopathology in diabetic db/db and nondiabetic db/m
mice with or without dRK6 treatment (Trichrome stain, 100). The
histopathology shows marked cardiac ﬁbrosis in diabetic db/db-dRK6
(D) compared with nondiabetic db/m and db/m-dRK6 mice (A and B)
and db/db control mice (C). Original magniﬁcation 200. Quantitative
assessment of the areas of ﬁbrosis in the myocardial tissue of the study
groups (E). *P < 0.01 compared with the other groups; n  4. (A
high-quality color digital representation of this ﬁgure is available in
the online issue.)
C.W. PARK AND ASSOCIATES
diabetes.diabetesjournals.org DIABETES, VOL. 58, NOVEMBER 2009 2671of db/db mice at much earlier ages. In this study, in
contrast to the db/db control mice, systemic inhibition
with dRK6 resulted in more severe systolic dysfunction and
gross cardiac hypertrophy and ﬁbrosis in the db/db mice at 5
months of age. The data from our study showed that the
direct effects of VEGF blockade, as well as the metabolic
abnormalities associated with diabetes such as hyperglyce-
mia, dyslipidemia, and hyperinsulinemia, might be important
to the development of pathologic conditions, including se-
vere cardiac hypertrophy, ﬁbrosis, and inﬂammation.
Data regarding circulating VEGF levels in diabetes are
highly discrepant. One study reported that plasma VEGF
levels were higher in type 2 diabetics that in controls (20).
In another study, plasma VEGF levels were elevated only
in type 2 diabetic patients with characteristics of athero-
sclerosis (21). In our study, there were sixfold higher
serum VEGF levels in db/db mice compared with db/m
mice. dRK6 treatment also increased the serum VEGF
level independently from diabetic conditions. It is well
known that as VEGF is a paracrine mediator, systemic
levels may not adequately reﬂect changes in the local
VEGF system (44). Therefore, elevated plasma VEGF
levels after dRK6 treatment might be a consequence of
feedback of systemic VEGF-VEGFR inhibition.
In summary, our results indicate that the systemic dRK6
completely inhibited endogenous cardioprotective mecha-
nisms through suppression of the VEGF-R2 and Akt-eNOS
axis in the heart of mice with type 2 diabetes and subse-
quently led to cardiac systolic dysfunction resulting from
cardiac ﬁbrosis and hypertrophy, which were related to
the regression of the microvasculature in the heart. These
changes were accompanied by intracardiac hypoxia and
oxidative stress. Therefore, the protective role of VEGF
appears to be predominantly dependent on its ability to
stimulate activation of Akt-eNOS in the endothelial cells in
tissues. Further clinical investigations are needed to eval-
uate whether VEGF inhibition using anti-VEGF agents for
the treatment of age-related macular diseases, various
cancers, and diabetic microvascular complications has
robust effects on the heart, especially in patients with type
2 diabetes.
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assessment of 8-OH-dG levels in the DNA from the hearts. *P < 0.05, compared with db/m,* * P < 0.01 compared with db/m and P < 0.05 compared
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